MétaCan
Menu
Retour à la cohorte
Enregistrement W1566894743

The Evolving Landscape for Pharmaceutical Product Liability Litigation in Canada

2006· article· en· W1566894743 sur OpenAlexaboutno aff
Gordon McKee, Robin D. Linley

Notice bibliographique

RevueDefense Counsel Journal · 2006
Typearticle
Langueen
DomaineHealth Professions
ThématiqueMedical Malpractice and Liability Issues
Établissements canadiensnon disponible
Organismes subventionnairesnon disponible
Mots-clésPlaintiffMass tortProduct liabilityClass actionLawLiabilityBusinessTortProduct (mathematics)Law and economicsEconomicsPolitical science
DOInon disponible

Résumé

récupéré en direct d'OpenAlex

ONLY a handful of pharmaceutical product liability cases have been tried in Canada, with the leading case being a decision from the mid-1980s involving reports of stroke in association with the use of oral contraceptives. (1) There are many reasons for this, of general application and unique to Canada. For example, damage awards in Canada have historically been much lower than in the U.S., and most provinces have a loser pays costs system. Accordingly, plaintiffs counsel are likely to be more careful to ensure they pursue only serious cases that they have good reason to believe have merit, and the cost of settling for defendants may often be less than the cost of defending. Further, because fewer cases are brought in Canada and plaintiff firms with inventories are rare, the benefits of a favorable trial verdict, beyond the individual case, are less compelling for both plaintiffs and defendants. However, recent developments in class actions (with a spillover effect on individual cases) and the expanded ability (both legal and practical) of plaintiffs' counsel to solicit new cases are changing the landscape for pharmaceutical product liability litigation in Canada. This article will (1) describe developments in mass tort litigation in Canada, with particular focus on pharmaceutical litigation, (2) describe the causes of action and remedies pursued by plaintiffs, and the defenses asserted, in such litigation; and, (3) discuss relevant aspects of Canadian procedure and trial practice. I. Mass Tort Treatment of Pharmaceutical Product Liability Litigation Class actions are permitted in all provinces in Canada, (3) with most having enacted specific class action legislation. (4) In the provinces that have enacted specific legislation other than Quebec, an action can be certified as a class action if the plaintiff can establish that (a) there is a sustainable cause of action (which will be assessed based on the pleadings alone), (b) there is an identifiable class with two or more persons, (c) the claims of those persons have substantial issues of or law in common, (d) a class action is the preferable procedure for resolving the common issues having regard to the objectives of the legislation--access to justice, judicial economy and behavior modification, and (e) the proposed representative plaintiff can adequately represent the interests of the class. (5) Although the Supreme Court of Canada has said that in considering whether a class action is the preferable procedure for resolution of the common issues, the court should look at preferability in the context of the action as a whole, including the individual issues, (6) the Supreme Court has also stated that predominance is not a requirement for class certification. Accordingly, the test for class certification is generally considered to be lower in Canada than in the U.S. As a result, a decision in the U.S. certifying a class may have persuasive significance in a Canadian class certification motion, but a decision in the U.S. denying class certification will likely carry much less weight. The Supreme Court of Canada has held that, before certification of a class action will be granted, the plaintiff must establish some basis in fact for each of the certification requirements, other than the requirement that the pleadings disclose a cause of action. (7) Responding counsel are permitted to file responsive evidence in support of their position on the certification motion, including expert evidence. The Supreme Court of Canada has held, however, that the certification stage is not meant to be a test of the merits of the action. (8) Much of the argument in Ontario product liability class certification hearings will be focused on whether the plaintiff has provided evidence that there is a way to prove class wide loss and, if not, how that renders the class definition overly broad, the alleged common issues not common and a class action not preferable. …

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,006
score de la tête « metaresearch » (Gemma)0,017
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Sans objet · Signal consensuel: aucune
GenreSignal candidat: Synthèse · Signal consensuel: aucune
Score de désaccord entre enseignants0,264
Score d'incertitude au seuil0,853

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0060,017
Méta-épidémiologie (sens strict)0,0000,001
Méta-épidémiologie (sens large)0,0010,001
Bibliométrie0,0070,007
Études des sciences et des technologies0,0180,013
Communication savante0,0150,004
Science ouverte0,0040,004
Intégrité de la recherche0,0070,008
Charge utile insuffisante (le modèle a refusé de juger)0,0160,001

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,040
Tête enseignante GPT0,387
Écart entre enseignants0,346 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeSans objet
Domainenon disponible
GenreSynthèse

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations0
Publié2006
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueDefense Counsel JournalMême sujetMedical Malpractice and Liability IssuesTravaux en français237 207